Cite
HARVARD Citation
Higgins, P. et al. (n.d.). P418 Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. Journal of Crohn's and colitis. p. S318. [Online].